Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23823295 | 0.67 | CSNK2A1 (0.37) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| SCHEMBL18405893 | 0.59 | LMNA (0.38) | MEN1KMT2A | |
| SCHEMBL12618885 | 0.57 | PDPK1 (0.44) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| SCHEMBL17281080 | 0.56 | PDPK1 (0.40) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| SCHEMBL19104229 | 0.55 | PARP1 (0.35) | RAB9A | |
| SCHEMBL17307154 | 0.55 | DPP4 (0.40) | MEN1CSNK2A1KMT2ADYRK1A | |
| SCHEMBL6364767 | 0.55 | LMNA (0.38) | MEN1KMT2A | |
| SCHEMBL16589274 | 0.55 | CSNK2A1 (0.38) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| SCHEMBL24854117 | 0.54 | LMNA (0.37) | MEN1KMT2A | |
| SCHEMBL824416 | 0.54 | CSNK2A1 (0.55) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | MEN1 791/4885CSNK2A2 360/4885RAB9A 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.